 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI, a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16th, 2022. 32nd Annual Oppenheimer Healthcare Conference virtual Date: March 16t 